In this manuscript we have demonstrated the potential of the SARS-CoV-2 E protein as a pharmaceutical target. Our study complements earlier docking screening by Gupta et al. , where more than 4000 of phytochemicals were tried on the same protein and three of those were found promising (belachinal, macaflavanone E, vibsanol B).